AEROBID Drug Patent Profile

Which patents cover Aerobid, and what generic alternatives are available?

Aerobid is a drug marketed by Roche Palo and is included in one NDA.

The generic ingredient in AEROBID is flunisolide. There are twelve drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the flunisolide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Aerobid

A generic version of AEROBID was approved as flunisolide by BAUSCH on February 20^th, 2002.

Summary for AEROBID

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	48
Patent Applications:	4,831
DailyMed Link:	AEROBID at DailyMed

US Patents and Regulatory Information for AEROBID

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Roche Palo	AEROBID	flunisolide	AEROSOL, METERED;INHALATION	018340-001	Aug 17, 1984		DISCN	No	No

Expired US Patents for AEROBID

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Roche Palo	AEROBID	flunisolide	AEROSOL, METERED;INHALATION	018340-001	Aug 17, 1984

International Patents for AEROBID

See the table below for patents covering AEROBID around the world.

Country	Patent Number	Title	Estimated Expiration
Hong Kong	8580	NEW FORM OF FLUNISOLIDE AND THE USE OF FLUNISOLIDE TO TREAT RESPIRATORY DISEASES
United Kingdom	1525181
Australia	506080
Japan	S6247880

AEROBID Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory of Aerosol Corticosteroid Devices: A Focus on AeroBid

Introduction

AeroBid, a brand name for the inhaler corticosteroid flunisolide, is a crucial medication in the management of respiratory conditions such as asthma and allergic rhinitis. Understanding the market dynamics and financial trajectory of AeroBid and similar inhaler corticosteroid devices is essential for manufacturers, investors, and healthcare professionals.

Market Size and Growth

The inhaler corticosteroid device market, which includes products like AeroBid, was valued at USD 616.09 million in 2023 and is projected to reach USD 886.4 million by 2031, growing at a Compound Annual Growth Rate (CAGR) of 4.6% from 2024 to 2031[1].

Key Drivers of Growth

Several factors drive the growth of the inhaler corticosteroid market:

Increasing Incidence of Respiratory Conditions

The rising incidence of respiratory diseases such as asthma, Chronic Obstructive Pulmonary Disease (COPD), and bronchitis significantly contributes to the demand for inhalable corticosteroids like AeroBid. Air pollution, which can exacerbate these conditions, further increases the need for immediate and effective treatments[4].

Technological Innovations

Advancements in inhalation devices, such as metered-dose inhalers (MDIs) and dry powder inhalers (DPIs), enhance the efficacy and accessibility of corticosteroid medications. These innovations are critical in optimizing drug delivery and improving patient outcomes[4].

Regulatory Environment

Regulatory updates emphasizing safety, efficacy, and environmental sustainability play a significant role in shaping the market. For instance, regulatory bodies ensure that drug prices are reasonable, which can impact the revenue of manufacturers[3].

Competitive Landscape

The market for inhaler corticosteroids is highly competitive, with several key players vying for market share. Companies like AstraZeneca, which received FDA approval for Airsupra (albuterol/budesonide) in January 2023, are continuously developing and launching new inhalation drugs to maintain their market positions[4].

Regional Market Dynamics

North America

North America holds the largest share of the inhalable drugs market, driven by high rates of respiratory diseases and a significant number of diabetes patients who require inhaled medications. The U.S. and Canada are key markets within this region[4].

Asia-Pacific

The Asia-Pacific region offers significant growth opportunities due to its large population and increasing healthcare spending. Emerging markets in this region are expected to drive future growth in the inhaler corticosteroid market[1][3].

Challenges and Restraints

Despite the growth potential, the market faces several challenges:

High Cost of Treatment

The high cost of treatment and potential misuse of funding can hinder market growth. Additionally, patent expirations leading to generic competition can impact pricing and market share[1].

Regulatory Hurdles

Strict regulatory environments can affect the pricing and availability of inhaler corticosteroids. For example, the Patented Medicine Prices Review Board (PMPRB) in Canada ensures that drug prices are reasonable, which can impact the revenue of manufacturers[3].

Lack of Awareness

A lack of awareness among patients and healthcare providers about the benefits and proper use of inhaler corticosteroids can also restrain market growth[1].

Opportunities for Growth

Emerging Markets

Regions like the Asia-Pacific offer substantial growth opportunities due to their large populations and increasing healthcare spending. These markets are expected to drive future growth in the inhaler corticosteroid market[1][3].

Technological Innovations

Advancements in delivery systems and formulations can enhance the efficacy and accessibility of inhaler corticosteroids. These innovations open up new market opportunities and improve patient outcomes[3].

Financial Trajectory

Revenue Forecast

The revenue from inhaler corticosteroids is expected to increase significantly over the forecast period, driven by increasing demand and expanding applications. The market is forecasted to grow in terms of both value and volume[3].

Pricing and Revenue

The pricing of inhaler corticosteroids is influenced by regulatory bodies to ensure it is not excessive. The competitive landscape, with top players competing to maintain market share, also affects revenue growth[3].

Partnerships and Innovations

Companies are focusing on partnerships to accelerate innovation and market penetration. For example, Aerovate Therapeutics is engaged in significant research and development efforts, including the IMPAHCT global Phase 2b/Phase 3 clinical trial for AV-101, which could potentially expand the market for inhalable drugs[2].

Patient Education and Support

Efforts to improve patient education and support, as well as sustainability initiatives, contribute to the market dynamics. These initiatives help in better disease management and increase the adoption of inhaler corticosteroids[1].

Impact of COVID-19

Despite the challenges posed by the COVID-19 pandemic, ongoing research and development efforts have continued to drive market evolution. The pandemic has highlighted the importance of effective respiratory treatments, further boosting the demand for inhaler corticosteroids[1].

"The increasing incidence of respiratory conditions like asthma, COPD, and bronchitis mainly drives the growth of the inhalable drugs market." - DelveInsight[4]

Key Takeaways

• The inhaler corticosteroid device market is expected to grow at a CAGR of 4.6% from 2024 to 2031.
• Technological innovations and increasing incidence of respiratory conditions are key drivers of market growth.
• Regulatory environments and competitive landscapes significantly impact market dynamics.
• Emerging markets, especially in the Asia-Pacific region, offer substantial growth opportunities.
• Patient education and support, along with sustainability initiatives, are crucial for market expansion.

FAQs

What is the projected market size for inhaler corticosteroid devices by 2031?

The inhaler corticosteroid device market is projected to reach USD 886.4 million by 2031[1].

What are the key drivers of growth in the inhaler corticosteroid market?

Key drivers include the increasing incidence of respiratory conditions, technological innovations, and regulatory updates emphasizing safety and efficacy[1][4].

How does the competitive landscape affect the market for inhaler corticosteroids?

The competitive landscape, with multiple players vying for market share, leads to pricing pressures and affects the financial performance of individual companies[1][3].

What are the major challenges facing the inhaler corticosteroid market?

Challenges include the high cost of treatment, regulatory hurdles, and a lack of awareness among patients and healthcare providers[1][3].

Which regions offer significant growth opportunities for inhaler corticosteroids?

The Asia-Pacific region and North America are key regions offering significant growth opportunities due to their large populations and increasing healthcare spending[1][4].

Sources

1. Inhaler Corticosteroid Device Market 2024-2031 Analysis Report - InsightAce Analytic
2. Aerovate Therapeutics Announces Full-Year 2023 Financial Results - Aerovate Therapeutics
3. Generic FLUNISOLIDE INN equivalents, drug patent expiry and market dynamics - Drug Patent Watch
4. Global Inhalable Drugs Market to Register Incremental Growth at a CAGR of ~6% by 2030 - DelveInsight via GlobeNewswire